<?xml version="1.0" encoding="UTF-8"?>
<p>Compared to imatinib, nilotinib may enable a greater proportion of patients with CML in chronic phase to achieve successful TFR if they receive nilotinib consolidation therapy for 2 years to sustain DMR; this is the same length of time required to achieve TFR in imatinib studies.
 <sup>
  <xref rid="b8-1031835" ref-type="bibr">8</xref>,
  <xref rid="b9-1031835" ref-type="bibr">9</xref>
 </sup> The aim of this STAT2 trial (Stop Tasigna
 <sup>Â®</sup> Trial) was to evaluate the efficacy of 2-year consolidation treatment with nilotinib for achieving successful TFR in patients with chronic phase CML.
</p>
